Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

11.08.2021 | review

Chronic lymphocytic leukaemia—what is new and notable in 2021, with a special focus on COVID-19

verfasst von: Katharina T. Prochazka, Peter Neumeister

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Summary

In the last few years, treatment of patients exhibiting chronic lymphocytic leukaemia has changed extensively due to advances in the development of targeted therapies. The role of immunochemotherapy has been for the most part replace and the guidelines have been modified accordingly. Herein, we give an overview on updated onkopedia guidelines, studded with updates of the landmark studies of the latest American Society of Hematology (ASH) meeting. In addition, since still crucial, recommendations concerning coronavirus disease 2019 (COVID-19) in chronic lymphocytic leukaemia patients will be covered.
Vorheriger Artikel SARS-CoV-2 vaccination in patients with solid tumors or hematological malignancies: Is the pandemic over for fully vaccinated patients?
Nächster Artikel New trends in autologous and allogeneic stem cell transplantation—an update from the annual ASH meeting 2020
Literatur
1.
2.
Shanafelt T, Wang XV, Kay NE, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381(5):432–43.CrossRef
3.
Woyach J, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517–28.CrossRef
4.
Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278–91.CrossRef
5.
Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225–36.CrossRef
6.
Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127(2):208–15.CrossRef
7.
Eichhorst B, Fink AM, Bahlo J, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17(7):928–42.CrossRef
8.
Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101–10.CrossRef
9.
Allan JN, Shanafelt T, Wiestner A, et al. Long-term efficacy of 1st-line ibrutinib for CLL with 4 years of FU in patients with TP53 aberrations: a pooled analysis from 4 clinical. Blood. 2020;136(Supplement 1):2219.CrossRef
10.
Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378:1107–20.CrossRef
11.
Kater A, Kipps TJ, Eichhorst B, et al. 5‑year analysis of Murano study demonstrates enduring uMRD in a subset of R/R CLL patients following fixed-duration VenR. Blood. 2020;136(Supplement 1):19–21.CrossRef
12.
Hallek M. The broadening landscape of targets and therapeutic options for CLL. In: EBMT handbook. 2021.
13.
Munir T, Brown JR, O’Brien S, et al. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94:1353–63.CrossRef
14.
Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (HELIOS): A randomized, double-blind, phase 3 study. Lancet Oncol. 2016;17:200–11.CrossRef
15.
Ghia P, Pluta A, Wach M, et al. ASCEND: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38:2849–61.CrossRef
16.
17.
Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881–92.CrossRef
18.
Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patient. Blood. 2020;135(21):1912–5.CrossRef
19.
20.
Roeker LE, Knorr DA, Pessin MS, et al. Anti-SARS-CoV‑2 antibody response in patients with chronic lymphocytic leukemia. Leukemia. 2020;34:3047–9.CrossRef
21.
Metadaten
Titel
Chronic lymphocytic leukaemia—what is new and notable in 2021, with a special focus on COVID-19
verfasst von
Katharina T. Prochazka
Peter Neumeister
Publikationsdatum
11.08.2021
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2021
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-021-00735-z

Weitere Artikel der Ausgabe 3/2021

Clinically relevant infections in hematatology and oncology

  • editorial

Multiple myeloma: my highlights at ASH 2020

  • Open Access
  • review

Best of SABCS 2020

  • editorial

Decision making in hematology—chronic myeloid leukemia

  • Open Access
  • case report

Interesting news from the annual meeting of the American Society of Hematology 2020

  • editorial

Cryptococcus neoformans meningitis in a patient with diffuse large B-cell lymphoma—a case report

  • case report